Ancogen

Quick links to important sections

Ancogen

Method of action: Miorelaxant

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ancogen

Ancogen: Foundational Definition and Purpose

Property Description
Active ingredient Acetaminophen, Chlorzoxazone
Form Tablets
Pharmacological class Non-opioid analgesic, Centrally acting skeletal muscle relaxant
Common purpose Relief of pain and muscle spasm
Origin Synthetic

What Type of Drug is Ancogen and Its Primary Classification?

Ancogen is a prescription-only fixed-dose combination (FDC) drug classified simultaneously as a non-opioid analgesic and a centrally acting skeletal muscle relaxant. This pharmaceutical preparation is typically available as tablets for oral administration, serving as a multi-modal agent for managing acute discomfort. The dual nature of this combination drug is a key differentiating factor, making it distinct from single-agent formulations often found over the counter. Acetaminophen, one of its key components, is used generally to relieve pain and reduce fever. The drug's therapeutic foundation is entirely synthetic, derived from chemically manufactured active pharmaceutical ingredients (APIs).


Composition: Acetaminophen, Chlorzoxazone, and the Combined Purpose

Ancogen's composition is defined by its two principal chemical substances: Acetaminophen (or Paracetamol) and Chlorzoxazone. Acetaminophen functions as the analgesic and antipyretic component, while Chlorzoxazone acts as the dedicated skeletal muscle relaxant. Chlorzoxazone's pharmacological class is a centrally acting muscle relaxant. This strategic pairing makes Ancogen an effective adjunct therapy designed to alleviate the dual burden of pain and muscle spasm often associated with acute painful musculoskeletal conditions. The medicine's general purpose is to provide integrated support by managing both pain signals and muscular hypertonicity.

Regulatory References

  1. Acetaminophen Drug Information

What side effects are possible with Ancogen?

Possible Side Effects and Safety Information

The safety profile for Ancogen, a fixed-dose combination of Acetaminophen and Chlorzoxazone, is defined by potential adverse effects across several organ systems, as documented in official regulatory sources. The most frequently reported reactions are associated with the muscle relaxant component and affect the Nervous System.

Frequency and System-Organ Effects

Side effects that are common in official labeling include drowsiness, dizziness, light-headedness, and a general feeling of malaise. Gastrointestinal disturbances, such as nausea, vomiting, and diarrhea, are also documented. Adverse reactions affecting the skin and subcutaneous tissue, such as allergic-type rashes and urticaria, may be observed.

Serious Adverse Reactions and Risk

Of particular regulatory concern are rare but serious adverse reactions. The Acetaminophen component carries a documented risk of acute liver failure, which may be fatal. Separately, Chlorzoxazone has been associated with serious hepatocellular toxicity in rare instances. Patients must be aware of signs of liver dysfunction, which may include jaundice, dark urine, or unusual tiredness. In very rare cases, blood dyscrasias (e.g., agranulocytosis) have been reported.

Safety Constraints and Special Populations

Official prescribing information states that the medicine is contraindicated in patients with known hypersensitivity to the components and in those with severe hepatic impairment or severe active liver disease. A key safety constraint is the potential for an additive effect when the medication is used concomitantly with alcohol or other Central Nervous System depressants. The safety of Chlorzoxazone during pregnancy has not been established and requires consideration of risk versus benefit.

Overdose and Emergency Response

Overdose and When to Seek Help

Ancogen overdose carries the risk of severe, life-threatening outcomes, reflecting the dual action of its components. Suspected overdose is a medical emergency requiring immediate attention regardless of initial symptoms.

The clinical presentation of overdose may begin with general symptoms such as severe drowsiness, confusion, lightheadedness, nausea, vomiting, and marked loss of muscle tone. The major risk is severe organ damage. Overdose is officially associated with the potential for acute liver failure (hepatotoxicity), which can be fatal. Other serious manifestations documented in regulatory labeling include respiratory depression, hypotension, and coma.

When to Seek Immediate Help

Government regulatory documents mandate that emergency medical assistance must be sought immediately for any known or suspected Ancogen overdose. Individuals must contact emergency services or the Poison Control Center right away. Monitoring in a hospital setting is required, along with continuous assessment of liver function.

In the case of Acetaminophen-related toxicity, the official antidote, N-acetylcysteine (NAC), is required to prevent or lessen hepatic injury. Management for the Chlorzoxazone component is entirely symptom-specific and supportive, focusing on maintaining a patent airway and hemodynamic stability. Patients with pre-existing liver disease or who consume three or more alcoholic beverages daily are noted to have an increased risk of severe toxicity.

Therapeutic Uses of Ancogen

What Ancogen Treats: Main Uses and Benefits

The medication is used in situations involving certain distressing symptoms associated with acute painful musculoskeletal conditions. Ancogen is commonly used to help with the symptom cluster of acute pain and involuntary skeletal muscle spasms, symptoms that create noticeable physiological strain, such as in cases of muscle strains, sprains, and low back discomfort.

The medication is considered relevant across conditions presenting with episodic manifestations.

Quick Fact: Symptomatic support for discomfort and tension

Its use is applicable within clinical settings that involve supportive treatment strategies like rest and physical therapy. By easing the distress from pain and spasm, Ancogen assists with maintaining functional stability.

“The combined approach may help patients cope more steadily with symptom fluctuations.”

Eligibility and Restrictions for Use

Eligibility Scope

The eligibility for Ancogen, a combination drug, is defined by regulatory bodies through specific population rules, restrictions, and absolute prohibitions. Use is generally established for adults requiring relief from discomfort associated with acute musculoskeletal conditions.

Category Eligibility Status (Regulatory Wording)
Contraindicated Populations Patients with severe hepatic impairment or severe active liver disease and individuals with a known hypersensitivity to Acetaminophen, Chlorzoxazone, or excipients.
Age-Related Rules Use is not established in the general pediatric population; children under 12 are generally not recommended to use this combination. Older adults require caution due to increased risk of age-related liver problems.
Hepatic & Comorbidity Contraindicated for patients taking other Acetaminophen products (to prevent overdose) or those with a history of chronic alcohol abuse (three or more drinks daily). Caution is required for patients with preexisting liver disease.
Pregnancy & Lactation Pregnancy: Use is generally permitted only if the potential benefit justifies the potential risk to the fetus. Lactation: Use is not recommended as safety in infants is not established, and it is unknown if Chlorzoxazone is excreted in breast milk.

Official Eligibility Statements

Official regulatory documents emphasize that the drug is contraindicated in patients with severe active liver disease and those with a known intolerance to any ingredient. Eligibility is strictly limited by the drug’s potential for hepatotoxicity, which mandates that use requires caution in patients with preexisting liver conditions or those who chronically consume alcohol. Furthermore, eligibility is restricted for children due to a lack of established safety data, and for nursing mothers as safety during lactation is unknown.

What should I know about interactions with other medicines?

The interaction profile for Ancogen is defined by regulatory constraints related to additive Central Nervous System (CNS) effects and the potential for hepatic toxicity.

Co-administration with other Central Nervous System (CNS) depressants—such as certain opioid pain relievers, benzodiazepines, barbiturates, and sedating antihistamines—may result in additive pharmacodynamic effects, leading to increased sedation or drowsiness. This interaction is primarily linked to the chlorzoxazone component. The chronic, excessive use of alcohol also substantially contributes to this additive CNS depressant effect.

The primary restriction involves the acetaminophen component and the risk of hepatotoxicity. Ancogen is formally prohibited for co-administration with any other product containing acetaminophen to prevent accidental overdose and the risk of severe liver damage. Furthermore, the use of Ancogen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Chronic consumption of alcohol significantly increases the risk of severe liver damage, especially when combined with acetaminophen.

Ancogen's acetaminophen component may also interact with certain blood thinners. Co-administration with Warfarin or other vitamin K antagonists can increase the International Normalized Ratio (INR), resulting in a modification of the anticoagulant effect. Caution is also advised for populations with preexisting liver disease, chronic malnutrition, or severe hypovolemia.

Mechanism of Action

Ancogen: Targeting the Source of Uncontrolled Growth

Ancogen acts as a targeted small molecule inhibitor that exerts its effect by targeting specific oncogenic tyrosine kinases within cells. By binding to the ATP-binding pocket of these hyperactive enzymes, Ancogen blocks the phosphorylation step, which is the foundational event in its mechanism of action. This interaction governs the immediate biochemical specificity of the compound.


Blocking Pro-Survival Signaling Cascades

The initial molecular inhibition propagates across key intracellular signaling pathways, primarily the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR axes. Ancogen attenuates the signals that regulate cell growth and survival. This disruption of pathways shifts the cellular balance, leading to the promotion of apoptosis (programmed cell death) in the highly dependent cell population, a core physiological consequence of the mechanism.


Modulating Pathological Tissue Support

Beyond its direct effects on cell survival, the mechanism of Ancogen extends to limiting support systems necessary for rapid tissue expansion. By inhibiting kinase activity, Ancogen restricts signaling crucial for angiogenesis (new blood vessel formation) and cellular migration. This action reduces the ability of the affected tissue to develop vascular supply and spread, contributing to systemic changes in proliferation rate and cellular migration potential.

Dosage and Administration Information

How to Use Ancogen

This section describes the administration and dosing guidelines for Ancogen, a fixed-dose combination of Acetaminophen and Chlorzoxazone.


Official Administration Protocol

Ancogen is formulated as a tablet and is intended for oral administration only. The use of this medicine is classified as short-term and is designated as an adjunct (supportive measure) to rest and physical therapy.

Feature Official Instruction Principle
Route & Form Administered by mouth in solid tablet form.
Timing in Meals The tablet may be taken with food or milk to potentially lessen gastrointestinal discomfort.
Preparation No preparation steps, such as dilution or reconstitution, are required.

Standard Dosing and Frequency

Administration is typically scheduled three to four times daily (TID or QID), which requires maintaining a consistent interval between doses, generally every six to eight hours. The dosing for the Chlorzoxazone component establishes the following regimen:

  • Typical Dose: For initial administration, the Chlorzoxazone component is generally set within the 250 mg to 500 mg range per dose.
  • Maximum Dose: The dosage may be increased up to a maximum of 750 mg per single dose; however, the dose should be reduced once acute symptomatic relief begins.

Specific Population Rules

Special consideration is given to certain patient populations. The safety and efficacy of the drug have not been established for pediatric use. For older adults, a lower starting dosage may be considered, and careful adherence to the minimum dosing interval is necessary due to potential age-related organ changes.

Recent Clinical Evidence

Research evidence / Overview of studies for Ancogen

The following information summarizes the scientific research available for Ancogen, a fixed-dose combination drug, focusing only on the structure of the clinical evaluation as reported in official and peer-reviewed sources.


Evidence for Use in Acute Painful Musculoskeletal Conditions

Clinical research for this combination drug has studied its use in patients experiencing acute painful musculoskeletal conditions where symptoms was observed in involuntary muscle spasm. The research was applied in studies examining patient-reported experiences of conditions characterized by fluctuating or episodic manifestations, such as acute low back discomfort, sprains, or strains.

What was studied: The core evidence comes from short-term Randomized Controlled Trials (RCTs). These trials was evaluated in the fixed-dose combination against comparators, including placebo or one of the active components alone, to research examined how symptoms change over time. The research primarily included adult patients and typically was observed in the combination drug alongside comparators such as a placebo or other non-opioid options used in research contexts involving fluctuating or unstable symptoms.

What the studies reported: Studies monitored outcomes related to physical discomfort as part of the clinical evaluation, such as pain intensity used in studies examining symptom intensity or variability on standardized scales, and outcomes reflecting daily functioning or activity level. Research provides context but not individual predictions. Systematic reviews note that certainty remains low to moderate regarding the overall research base for this combination drug, and evidence quality varies across studies.


The Scope of Short-Term Studies and Follow-up Duration

This part details the typical duration of clinical trials available for Ancogen, specifically addressing the scientific evidence that was observed in short periods (e.g., 5 to 10 days) and noting what is known and unknown about outcomes beyond that acute phase.

What remains uncertain: There is limited information for long-term outcomes regarding the fixed-dose combination. The long-term effects are not fully established because the trials were designed to observe only the acute symptom relief phase. Consequently, long-term outcomes are not well characterized in the official scientific literature for this combination. Comparative evidence is lacking for conditions involving longer periods of heightened symptoms.


What Research is Still Needed for Ancogen

This final section synthesizes the main evidence gaps identified by scientific and regulatory bodies, clarifying the key uncertainties related to long-term use, data consistency, and areas where more high-quality research is required.

Evidence Quality and Gaps: Scientific evaluations describe that the overall evidence quality varies across studies, and many early trials supporting the drug's components featured sample sizes were modest and follow-up durations were limited. Furthermore, comparative evidence is lacking in some areas, particularly concerning direct, high-quality head-to-head trials against all relevant alternative therapies. Official reviews highlight that the evidence is limited to provide definitive insight into symptom patterns over extended use.

Key Studies & References A comparative study of the efficacy and safety of thiocolchicoside and chlorzoxazone in patients with acute musculoskeletal pain

Frequently Asked Questions (FAQ)

Common questions about Ancogen (FAQ)

Q: Are the side effects of Ancogen always serious?

A: Official regulatory documents indicate that the majority of reported side effects are common, non-serious events, such as dizziness or drowsiness. However, the official warnings also describe rare, serious risks, including acute liver failure, which is why awareness of these risks is important.

Q: Can Ancogen cause problems with my liver or kidneys?

A: Regulatory information emphasizes warnings about the potential for severe liver (hepatic) toxicity associated with both components. Due to this risk, the drug is contraindicated (not to be used) in patients with severe active liver disease. Current official documents do not report evidence that the drug causes specific kidney (renal) damage.

Q: Does Ancogen interact with common pain relievers like ibuprofen?

A: Official warnings strictly prohibit combining Ancogen with any other product containing acetaminophen to prevent accidental overdose and severe liver damage. While the label does not explicitly name every common pain reliever, official information stresses the importance of checking labels of all co-administered medicines.

Q: Are there any specific food or beverage restrictions while on Ancogen?

A: Official documents state that the tablet may be taken with food or milk to help lessen potential gastrointestinal discomfort. The key restriction involves alcohol, as its chronic consumption significantly increases the risk of both liver damage and added Central Nervous System (CNS) depressant effects.

Q: Can Ancogen be taken during pregnancy?

A: According to regulatory information, use during pregnancy is generally permitted only after careful consideration. This is when the potential benefit to the patient is judged to justify the potential risk to the fetus.

Q: What is the risk of allergic reaction to Ancogen?

A: Official product information states that allergic-type skin reactions, such as rashes, have been reported rarely. The drug is contraindicated for individuals who have a known hypersensitivity (allergic reaction) to any of its ingredients.

Q: What are the major warnings listed on the Ancogen packaging?

A: The official safety information highlights the risk of severe liver toxicity, including potentially fatal acute liver failure, which is associated with both active components. Another major warning involves the risk of additive effects when combined with alcohol or other Central Nervous System (CNS) depressants, leading to increased sedation.

Q: How do regulatory bodies describe the 'efficacy' of Ancogen?

A: Official documents indicate that the drug is indicated as an adjunct (meaning supportive measure) to rest and physical therapy. This means it is authorized for the relief of discomfort associated with acute, painful musculoskeletal conditions, based on evidence from short-term clinical trials.

Q: Does Ancogen cause insomnia or fatigue?

A: Regulatory documents list common side effects that affect the Central Nervous System (CNS), including drowsiness and malaise (a general feeling of discomfort or illness often related to fatigue). Insomnia (difficulty sleeping) is not listed as a common adverse reaction in the official product information.

Q: Does Ancogen interact with common over-the-counter cold medicines?

A: Regulatory agencies strictly warn against combining Ancogen with any other product containing acetaminophen. This is to prevent accidental overdose and the risk of severe liver damage. The importance of checking labels of all medicines is emphasized, as many common over-the-counter cold, flu, or pain medicines contain acetaminophen.

Q: What is Ancogen used for besides the main condition it treats?

A: Official regulatory labels specify the drug's approved indication: it is used only as an adjunct (supportive measure) to rest and physical therapy. This use is restricted to the relief of discomfort associated with acute, painful musculoskeletal conditions.

Q: Do side effects from Ancogen go away after a while?

A: Regulatory information notes that some effects may go away as the body adjusts to the medicine. Official guidance suggests that persistent or bothersome side effects warrant discussion with a healthcare provider.

Q: Is it true that Ancogen can affect mood?

A: Official documents list common Central Nervous System (CNS) effects, such as drowsiness and dizziness. However, specific mood changes, like severe depression or agitation, are not typically listed as common or rare side effects in the core regulatory product information.

Q: How long does it usually take to feel the effects of Ancogen?

A: Studies examining the pharmacokinetics (how the body handles the drug) of the Chlorzoxazone component indicate that it is absorbed rapidly. Blood levels can typically be detected within the first 30 minutes, and peak concentrations are usually reached approximately 1 to 2 hours after the tablet is taken.

Q: If I stop taking Ancogen, how long does it stay in my system?

A: Official studies on the Chlorzoxazone component show that it is rapidly metabolized (broken down) in the liver and then quickly eliminated. Less than one percent of the component is excreted unchanged in the urine within 24 hours.

Q: What is the experience of people who have been on Ancogen for a long time?

A: Studies used to authorize the drug were designed to assess only short-term use, typically lasting between 5 to 10 days. Due to this, official literature provides limited information regarding the outcomes or effects of long-term use for this fixed-dose combination.

Q: What happens if someone who shouldn't use Ancogen takes it by mistake?

A: Official warnings state that taking the medicine when contraindicated or in excess carries a documented risk of severe liver damage, liver failure, and death. Signs associated with overdose may include severe drowsiness, nausea, vomiting, and difficulty breathing.

Q: Is Ancogen considered a standard treatment or a newer option?

A: Official documents classify Ancogen as an adjunct therapy, which means it is a supportive measure used alongside rest and physical therapy. This classification indicates it is not typically a stand-alone or first-line treatment.

Q: What should I do if I miss a scheduled dose of Ancogen?

A: Regulatory documents provide specific guidance for a missed dose in the package insert. This information should be strictly followed, as it details the specific timing rules for making up or skipping a scheduled dose to ensure safety.

Q: What is the risk of dependence or withdrawal with Ancogen?

A: The drug is not classified as a controlled substance by the DEA (Drug Enforcement Administration). Official labeling does not list dependence or withdrawal as a known risk for the fixed-dose combination.

Q: Does Ancogen have a 'black box' warning from regulatory bodies?

A: The Acetaminophen component is required to carry a prominent warning regarding the potential for severe liver injury. This serves as a key regulatory signal for serious risk, although the specific use of the term "Black Box Warning" may vary across individual product labels.

Q: Does Ancogen affect fertility or reproductive health?

A: Official product labels for the combination do not contain definitive information on the drug's effect on human fertility. Use during pregnancy is guided by an assessment of benefit versus risk, as safety is not fully established.

Q: What does 'contraindicated' mean for Ancogen?

A: Contraindicated is a medical term meaning that the drug is formally advised against use under certain circumstances, as the risk outweighs any potential benefit. For Ancogen, this applies to patients with a known hypersensitivity to the components or severe active liver disease.

Q: Is Ancogen a controlled substance?

A: The Chlorzoxazone component of the drug is not currently classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This means it does not fall under the strict federal regulations for narcotics or other addictive substances.

Q: Can Ancogen be used for symptoms like fatigue?

A: Official regulatory labels indicate the drug is only for the relief of discomfort associated with acute, painful musculoskeletal conditions. Fatigue is not an authorized use and is, in fact, listed as a potential common side effect (malaise), not a condition the drug treats.

Q: Why do official sources recommend regular monitoring while on Ancogen?

A: Official sources advise caution and likely monitoring for patients with pre-existing conditions that affect the liver. This is necessary because the drug is contraindicated in patients with severe hepatic impairment (liver damage) and carries a risk of liver injury.

Q: Do studies suggest a specific group of people responds best to Ancogen?

A: The clinical studies used for authorization primarily included adult patients experiencing acute painful musculoskeletal conditions. Official summaries of the research evidence do not note that a specific sub-group responds definitively better than others.

Q: Is it normal to feel [general, non-specific symptom] when starting Ancogen?

A: Official documents list common side effects that affect the Central Nervous System (CNS), such as drowsiness, dizziness, and light-headedness. These effects may be expected when first beginning treatment.

Q: Can Ancogen be split or crushed if it is a tablet?

A: Official administration instructions specify that the tablet is typically swallowed whole. They state that no preparation steps are required, indicating that the drug's form should not be altered (such as splitting or crushing) without guidance from a healthcare provider.

How should Ancogen be stored and disposed of?

Storage Requirements

Ancogen tablets must be stored according to regulatory requirements to maintain product stability. The medication should be kept at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Storage must be away from excess heat and moisture; therefore, the product should not be stored in a bathroom. To protect the contents from degradation, the medicine must be kept in its original container, tightly closed.

Child-Safety and Disposal

As a mandatory safety precaution, Ancogen must be stored out of the sight and reach of children and kept away from pets. Proper disposal of unneeded or expired tablets is essential. The preferred disposal method is through an authorized drug take-back program. If a take-back program is not available, the tablets must be mixed with an unappealing substance (like cat litter or coffee grounds) and sealed in a bag before being placed in the household trash, as specified by governmental guidelines for non-flushable medications. All personal information should be scratched out on the empty container prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ancogen found in:

A-Z Index: